BFRA Biofrontera AG

11.35
0  0%
Previous Close 11.35
Open
Price To Book 15.98
Market Cap 254,437,169
Shares 22,424,682
Volume 0
Short Ratio
Av. Daily Volume 174
Stock charts supplied by TradingView

NewsSee all news

  1. Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck

    Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today announced follow-up results for its

  2. Biofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter

    Leverkusen, Germany, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today announced its results for the first

  3. Biofrontera strengthens commercial focus with reorganization of its US business

    Leverkusen, Germany, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today announced a new organizational

  4. Extraordinary General Meeting of Biofrontera AG: Biofrontera Management Board supported by large majority

    Leverkusen, Germany, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today announced the results of the

  5. Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.

    Leverkusen, Germany, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, announced today that Christopher Pearson

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 patient enrollment has commenced with data due 2020.
Ameluz
Basal cell carcinoma
Phase 3 planned.
Ameluz
Acne
Phase 3 data met primary endpoint - March 20, 2019. sNDA filing 2020 (estimate only).
Ameluz
Actinic keratosis
Phase 3 planned.
Ameluz
Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Latest News

  1. Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck

    Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today announced follow-up results for its

  2. Biofrontera announces preliminary sales figures for the full year 2019, record sales in the 4th quarter

    Leverkusen, Germany, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today announced its results for the first

  3. Biofrontera strengthens commercial focus with reorganization of its US business

    Leverkusen, Germany, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today announced a new organizational

  4. Extraordinary General Meeting of Biofrontera AG: Biofrontera Management Board supported by large majority

    Leverkusen, Germany, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today announced the results of the

  5. Christopher Pearson appointed new Chief Commercial Officer at US subsidiary Biofrontera Inc.

    Leverkusen, Germany, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, announced today that Christopher Pearson

  6. Biofrontera to Participate in Upcoming Investor Conferences

    Leverkusen, Germany, Nov. 22, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today announced its participation

  7. Biofrontera Reports Third Quarter 2019 Financial Results and Revises Guidance

    Leverkusen, Germany, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today announced its results for the first

  8. Biofrontera Announces Conference Call on November 19, 2019 to Discuss Third Quarter 2019 Financial Results

    Leverkusen, Germany, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, will be releasing its financial results

  9. Biofrontera Receives Award at Fall Clinical Dermatology Conference 2019

    Leverkusen, Germany, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, was presented with the "Poster of the

  10. Biofrontera reports preliminary unaudited sales revenue for the first nine months of 2019

    Leverkusen, Germany, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company" or the "Biofrontera-group"), an international biopharmaceutical company, today reports

  11. Biofrontera to present at the Baader Investment Conference

    Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, announced that Prof. Dr. Hermann

  12. Biofrontera Files Label Extension for Ameluz® in EU to include Treatment of Actinic Keratosis on Extremities and Trunk/Neck

    Leverkusen, Germany, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, has filed a label extension for Ameluz®

  13. Biofrontera to participate at the Lake Street Capital Markets 2019 Best Ideas Growth (BIG) Conference

    Leverkusen, Germany, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, will be participating in the Lake Street

  14. Biofrontera shows robust growth during first six months of 2019

    Leverkusen, Germany, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ:BFRA, Frankfurt Stock Exchange: B8F)) (the "Company"), an international biopharmaceutical company, today reported its results for the first